Endava plc
DAVA · NYSE
Market closed$2.82$0.020000 (+0.71%)After hours $2.82 · 0.00%
Key statistics
Previous close$2.80
Open$2.80
Day high$2.82
Day low$2.71
52-week high$15.20
52-week low$2.55
Market cap151.08M
Volume165.53K
Average volume385.67K
P/E ratio3.52
Forward P/E—
EPS0.80
Dividend yield0.00%
Market context
Why it moved
Endava (DAVA) shares edged lower amid continued investor concern following recent analyst fair value cuts tied to prior guidance reductions and a quarterly earnings miss, which have weighed on sentiment and kept selling pressure on the stock.
What is happening
Recent company-specific developments and publisher coverage.
Moomoo · July 9, 2026TD Cowen Maintains Endava(DAVA.US) With Hold Rating, Cuts Target Price to $3.5Business Wire · June 30, 2026Endava Partners with Wiz to Deliver Integrated Cloud Security for Enterprise AI AdoptionInvesting.com · May 27, 2026Guggenheim downgrades Endava stock rating to neutral on weak resultsInvesting.com · May 21, 2026Earnings call transcript: Endava’s Q3 2026 EPS misses, stock drops 20%Business Wire · May 21, 2026Endava Announces Third Quarter Fiscal Year 2026 ResultsInvesting.com · May 21, 2026Endava tumbles 21% as revenue misses analyst estimates, guidance disappointsQuiver Quantitative · May 21, 2026ENDAVA ($DAVA) Releases Q3 2026 EarningsBusiness Wire · February 19, 2026Endava Announces Second Quarter Fiscal Year 2026 Results Benzinga · July 9, 2026TD Cowen Maintains Hold on Endava, Lowers Price Target to $3.5 Mt Newswire · June 30, 2026Endava Teams Up With Wiz to Strengthen Multi-Cloud Security Mt Newswire · May 27, 2026Guggenheim Downgrades Endava to Neutral From Buy Mt Newswire · May 22, 2026Endava Shares Fall After JPMorgan Downgrade Benzinga · May 22, 2026Endava Analysts Slash Their Forecasts Following Downbeat Q3 Results Benzinga · May 22, 2026Morgan Stanley Maintains Equal-Weight on Endava, Lowers Price Target to $4 Benzinga · May 22, 2026JP Morgan Downgrades Endava to Underweight, Lowers Price Target to $5 Mt Newswire · May 22, 2026JPMorgan Downgrades Endava to Underweight From Neutral, Adjusts Price Target to $5 From $9